Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06163898 · ClinicalTrials.gov registry record · Phase 1

A Study to Evaluate Alnuctamab in Combination With Mezigdomide in Participants With Relapsed and/or Refractory Multiple Myeloma

A Phase 1 study of Multiple Myeloma, sponsored by Celgene.

Active
Registry status
Phase 1
Development phase
156
Enrollment target
6
Study locations

NCT06163898 is a Phase 1 study of Multiple Myeloma that is active but no longer recruiting, run by Celgene. The registered enrollment target is 156 participants, below the 546-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (71% lower). The trial reports 6 study locations across 5 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06163898, a Phase 1 study of Multiple Myeloma, is active but no longer recruiting, sponsored by Celgene.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
156 participants
Enrollment target
6
Study locations

Study Summary

The purpose of this study is to determine the recommended dose and schedule, and evaluate the safety and preliminary efficacy of alnuctamab in combination with mezigdomide in participants with relapsed and/or refractory multiple myeloma.

Conditions Studied

Multiple Myeloma

Interventions

  • DRUG Dexamethasone
  • DRUG Mezigdomide
  • DRUG Alnuctamab

Study Locations (6)

Central District

  • Local Institution - 0021 - Petah Tikva
  • Local Institution - 0030 - Ramat Gan

Alabama

  • Local Institution - 0033 - Birmingham

Connecticut

  • Local Institution - 0035 - New Haven

New York

  • Local Institution - 0018 - New York

Other

  • Local Institution - 0020 - Jerusalem

Trial Details

FieldValue
Enrollment Target 156 participants
Start Date 2024-02-27
Est. Completion 2025-05-30
Phase Phase 1

Sponsor

Celgene

308 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06163898

The ClinicalTrials.gov registry entry for NCT06163898 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 156 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 546-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (71% lower). The listed sponsor is Celgene, which has 308 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Multiple Myeloma appearing as the primary indexed condition, and to 3 interventions - of which Dexamethasone is the first listed.

NCT06163898 reports 6 study locations spanning 5 distinct geographic areas - top geographies include Central District, Alabama, Connecticut.

Frequently Asked Questions

What is clinical trial NCT06163898 about?

NCT06163898 is a clinical study titled "A Study to Evaluate Alnuctamab in Combination With Mezigdomide in Participants With Relapsed and/or Refractory Multiple Myeloma". The purpose of this study is to determine the recommended dose and schedule, and evaluate the safety and preliminary efficacy of alnuctamab in combination with mezigdomide in participants with relapsed and/or refractory multiple myeloma.

What is the current status of trial NCT06163898?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 156 participants. The study started on 2024-02-27. Estimated completion is 2025-05-30.

What conditions does trial NCT06163898 study?

This clinical trial studies the following conditions: Multiple Myeloma.

What interventions are being tested in trial NCT06163898?

The interventions under investigation include: Dexamethasone (DRUG), Mezigdomide (DRUG), Alnuctamab (DRUG).

Who is sponsoring clinical trial NCT06163898?

This trial is sponsored by Celgene, which has 308 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06163898 being conducted?

This trial has 6 study locations across Alabama, Connecticut, New York, Central District. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Multiple Myeloma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Multiple Myeloma

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.